Dr. (Hayes) Bouknight was a graduate Scholar in the NCI Molecular Pathology Graduate Partnership Program in partnership with Michigan State University and the National Institute of Diabetes and Digestive and Kidney Diseases, from 2005 – 2010. 

Dr. (Hayes) Bouknight received her B.S. from Fort Valley State University and her D.V.M. from Tuskegee University in 2004. After graduation, Dr. Hayes (Bouknight) pursued a residency in anatomic pathology in the Department of Pathobiology and Diagnostic Investigation at Michigan State University. In 2005, she was accepted into the NCI Molecular Pathology Graduate Partnership Program to continue graduate course work and training as a diagnostic pathologist at MSU. Following completion of her diagnostic training and course work, Dr. Hayes (Bouknight) accomplished board certification in anatomic pathology by The American College of Veterinary Pathologists in 2007. She then relocated to the NIH, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD to begin her dissertation research. Her research focused on the transcriptional regulation of adipocyte differentiation in a laboratory headed by Elisabetta Muller, Ph.D., within the NIDDK Genetics of Development and Disease Branch. Members of her graduate guidance committee included: Matti Kiupel D.V.M, Ph.D., Diplomate, The American College of Veterinary Pathologists (chair), Elisabetta Mueller, Ph.D., James Wagner,M.B.A., Ph.D., and Mark Simpson, D.V.M, Ph.D., Diplomate, The American College of Veterinary Pathologists. After receiving her Ph.D., Dr. (Hayes) Bouknight was employed by Lexicon Pharmaceuticals as a veterinary pathologist.  She now resides in Raleigh-Durham, NC where she serves as a veterinary pathologist for Charles River Laboratories.  

Shive was a graduate scholar in the NCI molecular pathology GPP in partnership with the University of Maryland and the National Cancer Institute, from 2006 to 2010. 

Dr. Shive received her B.S. from the University of Arizona and her D.V.M from North Carolina State University, College of Veterinary Medicine in 2004. Following graduation, she joined the residency program in anatomic pathology in the Department of Pathobiology at Texas A&M University, College of Veterinary Medicine, wehre she trained for two years. She was accepted as a graduate fellow in molecular pathology through the Graduate Partnership Program (GPP) at the National Cancer Institute in 2006. While pursuing graduate training at the NCI, she achieved board certification in Anatomic Pathology by the American College of Veterinary Pathologists in 2007. Dr. Shive completed her dissertation research in the research laboratory of Dennis Hickstein, M.D., in the Experimental Transplantation and Immunology Branch at the NCI. The dissertation project was focused on investigating germline mutations in the breast cancer-2 gene (brca2) in the zebrafish (Danio rerio). These studies revealed a critical role for brca2 in ovarian development, and provide new insights into brca2 mutation and cancer susceptibility. Members of her graduate guidance committee included: Siba Samal, BVSc, Ph.D., Diplomate, The American College of Veterinary Microbiologists (chair); Dennis Hickstein, M.D.; Paul Liu, M.D., Ph.D. (NHGRI); Mark Simpson, D.V.M, Ph.D., Diplomate, The American College of Veterinary Pathologists; Liangli Yu, Ph.D. and Xiaoping Zhu, D.V.M, Ph.D. After receiving her Ph.D. in 2010, Dr. Shive accepted a Staff Scientist position in the NCI, CCR, Transplantation and Immunology Branch, where she continued her cancer research using the zebrafish model.  She served as an assistant professor at North Carolina State University, Raleigh, NC for several years before moving to Ohio State University, Columbus, Ohio. 

Dr. Woolard was a graduate scholar in the NCI Molecular Pathology GPP in partnership with the North Carolina State University and the National Cancer Institute, from 2003 - 2010. 

Dr. Woolard graduated from veterinary school at North Carolina State in 2003.  Following graduation, Dr. Woolard remained at the College of Veterinary Medicine, entered the molecular pathology GPP as a Cancer Research Training Fellow and undertook graduate course work and training in anatomic pathology. During his diagnostic pathology training he formed an interest in neuro-pathology and in neural stem cell biology. Following these interests, he completed his Ph.D. dissertation research in the comparative genomics driving canine and human gliomagenesis, focusing on the establishment of the dog as a spontaneous model for human gliomagenesis, in the Neuro-Oncology Branch headed by Howard Fine, M.D. in Bethesda, MD.  Dr. Woolard’s graduate committee was headed by Howard A. Fine, M.D., head of the Neuro-Oncology Branch.  Other members of his graduate committee included: John Cullen, V.M.D., Ph.D., Diplomate, The American College of Veterinary Pathologists; Matthew Breen, Ph.D., Diplomate, The American College of Veterinary Pathologists; Dave Malarkey, D.V.M., Ph.D., Diplomate, The American College of Veterinary Pathologists; and Mark Simpson D.V.M., Ph.D., Diplomate, The American College of Veterinary Pathologists.  After receiving his Ph.D. he continued his research in the Fine laboratory comparing canine and human glioma stem cells to physiologic embryonic and adult canine neural stem cells, to elicit signaling pathways involved in self-renewal commonly expressed in both populations. He believes the dog represents a unique opportunity for meaningful comparative research of this spontaneous, heterogeneous tumor in humans through its remarkable genetic and physiologic similarity to human disease. Through comparative Genomic analysis and investigation into self-renewal signaling pathways shared between human and canine glioma stem cells, and ultimately canine embryonic stem cells, he hopes not only to better understand the process of glioma development and progression, but also to identify future molecular targets for therapeutic intervention.  Dr. Woolard is currently an assistant professor of Pathology, Microbiology & Immunology at the University of California, Davis School of Veterinary Medicine. 

Hoenerhoff was a graduate fellow in the NCI molecular pathology GPP in partnership with Michigan State University from 2004-2008. 

Dr. Hoenerhoff received his DVM from Michigan State University College of Veterinary Medicine in 1998, followed by three years working as a clinician in a small animal and emergency practice. In 2001, Dr. Hoenerhoff returned to Michigan State University to pursue a residency in anatomic veterinary pathology in the Department of Pathobiology and Diagnostic Investigation. Following completion of his residency, Dr. Hoenerhoff received board certification in by The American College of Veterinary Pathologists in 2004, while pursuing graduate training in comparative pathology through the Graduate Partnership Program at the National Cancer Institute at the National Institutes of Health in Bethesda, MD. His dissertation research focused on breast cancer biology, breast cancer stem cells, and genetically engineered mouse (GEM) models of breast cancer in the Transgenic Oncogenesis Laboratory, led by Jeffrey Green, M.D., in the Laboratory of Cancer Biology and Genetics. Dr. Hoenerhoff defended his dissertation research and received his PhD degree from Michigan State University in May of 2008. The title of his Ph.D. dissertation is “BMI1 collaborates with HRAS to promote mammary tumorigenesis and metastasis”. Members of his graduate guidance committee included: Thomas Mullaney, D.V.M. Ph.D., The American College of Veterinary Pathologists, (Chair); Kurt Williams, D.V.M., Ph.D., Diplomate, The American College of Veterinary Pathologists; P.S. MohanKumar, B.V.Sc., Ph.D; Michael Scott, D.V.M., Ph.D., Diplomate, The American College of Veterinary Pathologists; Vilma Yuzbasiyan-Gurkan, Ph.D.; Jeff Green, M.D. and Mark Simpson, D.V.M., Ph.D., Diplomate, The American College of Veterinary Pathologists.  Following completion of his Ph.D., Dr. Hoenerhoff joined the Cellular and Molecular Pathology Branch at the National Institute of Environmental Health Sciences in the Research Triangle Park, NC, as Head of Investigative Pathology (2008-2013). His research focused on genetic and epigenetic mechanisms of chemically induced carcinogenesis and toxicity in National Toxicology Program (NTP) studies.  He has now returned to Michigan, his home state, where he accepted a position at the University of Michigan, Ann Arbor, MI as an associate professor.      

Dr. Caudell was a graduate fellow in the NCI molecular pathology GPP in partnership with University of Maryland from 2003-2008.  He completed his dissertation research in the Genetics Branch, under the mentorship of Peter Aplan, M.D. 

Dr. Caudell received his D.V.M. degree from Virginia Tech in 2000, followed by a residency in Anatomic Pathology in the Department of Pathobiology at Oklahoma State University, completed in 2003. Following his residency, Dr. Caudell pursued graduate training in comparative molecular pathology through the Graduate Partnership Program at the National Cancer Institute, Bethesda, MD. He completed his dissertation research in mouse models of human leukemia in the Genetics Branch, Leukemogenesis Section headed by Peter D. Aplan, M.D. Dr. Caudell defended his dissertation research and was awarded his Ph.D. degree from the University of Maryland in June 2008. The title of his Ph.D. dissertation is "Development of a mouse model for the t(10;11)(p13;q14) chromosomal translocation associated with acute leukemia in humans". Members of his graduate committee included: Siba K. Samal, B.V.Sc. Ph.D., Diplomate, The American College of Veterinary Microbiologists (Chair); Peter D. Aplan, M.D. (Co-Chair); Nathanial Tablante, D.V.M.,M.S., Diplomate, The American College of Poultry Veterinarians; R. Mark Simpson, D.V.M., Ph.D., Diplomate, The American College of Veterinary Pathologists; Iqbal Hamza, Ph.D. and Nickolas Zimmerman, Ph.D. After receiving his Ph.D., Dr. Caudell continued his research as a tenure track Assistant Professor in Pathology, in the Department of Pathobiology and Biomedical Sciences at Virginia Tech, Blacksburg, VA.  He remained in Blacksburg from 2009-2013.  In January, 2013, he continued to pursue his career as an assistant professor at Wake Forest School of Medicine, Winston Salem, North Carolina. After two years of helping to build reserach programs and resources there, he has been named the new Associate Director of the Center for Comparative Medicine Research.  

Dr. Glabman was a graduate scholar in the NIH Comparative Biomedical Scientist Training Program in partnership with Michigan State University and the National Cancer Institute, 2017-2023. 

Prior to joining the program, Dr. Glabman received a master's degree in public health science from Tulane University in 2010 and her VMD in 2017 from the University of Pennsylvania. She completed her diagnostic pathology training and didactic graduate coursework at Michigan State University. She continued her research in the NCI's Molecular Imaging Branch under the mentorship of Dr. Peter Choyke and Dr. Noriko Sato. Her research centered on understanding the protumorigenic role of cancer-associated fibroblasts (CAFs) within the tumor microenvironment of mammary tumors using an MMTV-PyVT mouse model, and targeting CAFs using near-infrared photoimmunotherapy (NIR-PIT). 

Members of her graduate committee included: Gisela Hussey DVM, PhD, Dalen Agnew DVM PhD DACVP, Margaret Petroff PhD, Noriko Sato MD PhD, Peter Choyke MD and Mark Simpson DVM PhD DACVP. 

Dr. Beck is a graduate scholar in the NIH Comparative Biomedical Scientist Training Program in partnership with Purdue University and the National Cancer Institute, July 2013 - December 2020.

Prior to joining the program, Dr. Beck received her D.V.M in May of 2013 from the University of Georgia. She competed her initial diagnostic pathology training and pre-dissertation research at Purdue University in West Lafayette, Indiana in 2015. At NCI, she is investigating the roles of cellular senescence in cancer and aging with particular focus on the use of senescence-inducing therapies in the treatment of glioblastoma multiforme and on mechanisms of radiation-induced brain injury in cancer survivors.

Dr. Flis was a graduate scholar in the NIH Comparative Biomedical Scientist Training Program in partnership with North Carolina State University and the National Cancer Institute, 2017 –2023.

Prior to joining the program, Dr. Flis received her D.V.M in May of 2017 from Purdue University. She completed her diagnostic pathology training and didactic graduate coursework at North Carolina State University in Raleigh, NC. She then completed her dissertation research in the NCI Laboratory of Human Carcinogenesis under the mentorship of Bríd M. Ryan and Stefan Ambs. Her research focused on characterizing the antiproliferative signaling mechanisms of dopamine receptor D1 (DRD1) in lung cancer cells and investigating those mechanisms’ synergy with EGFR inhibition by small molecules. She received the Society of Toxicologic Pathology Resident and Student Poster Award in 2022 for her poster presentation titled “Investigating the Interactions of Dopamine Receptor D1 in Lung Cancer.”

Members of her graduate committee included: Bríd M. Ryan PhD MPH, Stefan Ambs PhD MPH, R. Mark Simpson DVM PhD DACVP, John Cullen DVM PhD DACVP, Michael W. Nolan DVM PhD DACVR, and committee head Philip L. Sannes PhD. 

Dr. Flis is now an investigative pathologist with Sanofi in Cambridge, MA.

Dr. Peat was a graduate scholar in the NIH Comparative Biomedical Scientist Training Program in partnership with Purdue University and the National Cancer Institute, July 2015 - 2020.

Prior to joining the program, Dr. Peat received his D.V.M in May of 2014 from the Purdue University. He recently completed his diagnostic pathology training and the university portion of his research at Purdue University in West Lafayette, Indiana and was in the Mock Laboratory at the NCI. His research interests include discovering novel drug combinations to treat multiple myeloma in humans, understanding mechanisms of drug synergy, and developing new animal models to test drug sensitivity. 

Dr. Peat is the recipient of the 2018 Dennis Sikes Award and the 2019 Center for Cancer Research Fellows and Young Investigators Travel Award for an Outstanding Oral Presentation.

Dr. Peat is now a anatomic pathologist for LabCorp in Greenfield, Indiana.

Dr. Michael was a graduate scholar in the NIH Comparative Biomedical Scientist Training Program in partnership with the University of Maryland and the National Cancer Institute, July 2012-October 2018.

Dr. Michael received her bachelor’s degree from Carleton College and her D.V.M. from the University of Minnesota in May of 2008.  Prior to joining the program she completed a residency in clinical pathology at the University of Minnesota.  Her research focuses on the role of childhood UV exposure in the development of melanocytic moles and the progression to melanoma. 

She recently won an NIH Graduate Student Research Award for her work and has given presentations at the Society for Melanoma Research annual meetings.